Ancora Heart, Inc.

Ancora Heart, Inc. is a medical device company located in Santa Clara, California. The company focuses on developing innovative treatments for heart failure, particularly for patients with heart failure with reduced ejection fraction (HFrEF). Their mission is to enhance patient well-being and longevity by addressing the structural and functional issues caused by heart failure. The flagship product, the AccuCinch® Ventricular Restoration System, is the first completely transcatheter device designed to restore the structure and function of the enlarged left ventricle. This system aims to reduce the size of the left ventricle, decrease wall stress, and strengthen the heart wall, ultimately improving heart function and quality of life for patients. The AccuCinch System received Breakthrough Device Designation from the FDA in 2022 and is currently undergoing clinical trials to validate its safety and effectiveness. Led by President and CEO Jeff Closs, Ancora Heart engages with patients, clinical investigators, and healthcare providers to support clinical studies and promote the adoption of its therapy. The company is committed to advancing heart failure treatment through its innovative solutions and ongoing research.

• Employees 78
• Founded 2002
• Annual Revenue $15000000
• Total Funding $151260254